Korean company Medison, best known as a maker of high-quality ultrasound equipment, will soon file for court receivership, according to Asian news services. The company is laboring
Korean company Medison, best known as a maker of high-quality ultrasound equipment, will soon file for court receivership, according to Asian news services. The company is laboring under a huge debt, reported Asia Pulse, and can no longer service its loans. Medison holds 247.2 billion won (US$185.4 million) in interest-bearing debt and has short-term liabilities maturing in 2003 exceeding 175 billion won (US$131.25 million). Company executives contacted creditors Jan. 29 about their decision to file for bankruptcy after missing a 4.4 billion won (US$3.3 million) loan payment, according to the Korea Times.
Founded in 1985, Medison quickly became an international icon for Korean prosperity, capturing a majority of the Korean marketplace for ultrasound and forging deals with international vendors to supply low-cost ultrasound equipment. The company also was a major promoter of real-time 3D ultrasound systems. Its demise appears to be due primarily to ill-considered ventures in Web-based businesses. The plunge in stock prices of companies in which Medison had invested borrowed funds began to destabilize the company more than a year ago, according to Asia Pulse. Medison posted 116 billion won in net losses in 2000 compared with 52.3 billion won in net profits the previous year. In a bid to remain solvent, Medison has been selling assets. Among these was its share in Kretztechnik, which GE purchased in October (SCAN 10/17/01). A statement released by Medison and its creditors, reported by Asia Pulse, said company executives are seeking corporate alliances and foreign investments.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.